Compare DSL & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSL | ALVO |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1032 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2013 | N/A |
| Metric | DSL | ALVO |
|---|---|---|
| Price | $10.89 | $3.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 639.0K | 587.6K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 12.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.28 |
| Revenue Next Year | N/A | $21.29 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.49 | $3.03 |
| 52 Week High | $12.67 | $11.85 |
| Indicator | DSL | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 42.97 |
| Support Level | N/A | $3.03 |
| Resistance Level | $11.45 | $4.17 |
| Average True Range (ATR) | 0.15 | 0.22 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 65.81 | 45.25 |
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.